Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.

Laith J Abu-Raddad ORCID logo; Hiam Chemaitelly ORCID logo; Hadi MYassine; Fatiha MBenslimane; Hebah AAl Khatib; PatrickTang; Joel AMalek; PeterCoyle; Houssein HAyoub; ZainaAl Kanaani; +13 more... EinasAl Kuwari; AndrewJeremijenko; Anvar HassanKaleeckal; Ali NizarLatif; Riyazuddin MohammadShaik; Hanan FAbdul Rahim; Gheyath KNasrallah; Mohamed GhaithAl Kuwari; Hamad EidAl Romaihi; Mohamed HAl-Thani; AbdullatifAl Khal; Adeel AButt; RobertoBertollini; (2021) Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. Journal of travel medicine, 28 (7). taab083-. ISSN 1195-1982 DOI: 10.1093/jtm/taab083
Copy

Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week-by-week after the first dose. 75% of protection against infection and disease is reached 15-21 daysafter the first dose. Protection increased most rapidly against hospitalization and death and slowest against B.1.351infection.While protection of one dose beyond 21 days could not be assessed, findings support delaying the second vaccinedosein situations of limited vaccine suppliesand high incidences.



picture_as_pdf
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download

Explore Further

Read more research from the creator(s):

Find work associated with the faculties and division(s):

Find work associated with the research centre(s):

Find work from this publication: